kabutan

Kringle Pharma hits daily limit up on patent registration for chronic spinal cord injury treatment

Wed Apr 1, 2026 10:14 am JST Catalyst

Kringle Pharma,Inc. <4884> surged to its daily limit up of \80 above the previous trading day's close and remained locked at bid-only quotation at that level. On the 1st, the company announced that a patent related to a new treatment for chronic spinal cord injury, jointly filed with Keio University, has been registered in Japan. The announcement attracted buying interest. The patent is based on research findings that demonstrated recovery of motor function and urinary function through the combined use of human iPS-derived cell transplantation developed by Keio University and a scaffold containing hepatocyte growth factor (HGF) developed by Kringle Pharma. The company is currently advancing the development of an HGF-based therapeutic drug for acute spinal cord injury and is preparing for an additional Phase 3 clinical trial.

Source: MINKABU PRESS

Related Articles